Program
tavapadon
Also written as “Tavapadon”, “PF-06649751” and “0.5 mg PF-06649751”.
Its studies are mostly in Parkinson Disease · Renal Insufficiency, led by 2 companies.
Drug pageTavapadon: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 5, 2013.
- Feb 20, 2015Phase 1 study in Parkinson DiseasePfizer · NCT02373072 · 18 enrolled · United States, Belgium
- Jan 29, 2016Phase 2 study in Parkinson DiseasePfizer · NCT02687542 · 108 enrolled · United States, Canada, France and more
- Jul 25, 2016Phase 2 study in Parkinson DiseasePfizer · NCT02847650 · 57 enrolled · United States, France, Germany and more
- Apr 7, 2017Phase 1 study in HealthyPfizer · NCT03121664 · 11 enrolled · Belgium
- Jun 9, 2017Phase 2 study in Parkinson DiseasePfizer · NCT03185481 · 5 enrolled · United States
- Jun 9, 2018Named tavapadonINNProposed as its International Nonproprietary Name in WHO's List 119 · before, PF-06649751, CVL-751
- Dec 13, 2019AbbVie’s first study: phase 3 study in Parkinson DiseaseNew to AbbVieAbbVie · NCT04201093 · 529 enrolled · United States, Australia, Bulgaria and more
- Jan 7, 2020Phase 3 study in Parkinson DiseaseAbbVie · NCT04223193 · 304 enrolled · United States, Australia, France and more
- Jan 22, 20202 phase 1 studiesAbbVie · NCT04241393, NCT04295642
- Sep 2, 2020Phase 3 study in Parkinson DiseaseAbbVie · NCT04542499 · 507 enrolled · United States, Australia, Bulgaria and more
- Feb 12, 2021Phase 3 study in Parkinson DiseaseAbbVie · NCT04760769 · 992 enrolled · United States, Australia, Bulgaria and more
- May 30, 20222 phase 1 studiesAbbVie · NCT05404542, NCT05404529
- Oct 12, 2022Phase 1 study in Parkinson DiseaseAbbVie · NCT05581823 · 16 enrolled · United States
- Nov 2, 2022Phase 1 study in Parkinson DiseaseAbbVie · NCT05610189 · 25 enrolled · United States
- Mar 20, 2025Phase 1 study in Healthy VolunteerAbbVie · NCT06895356 · 83 enrolled · United States
TargetBeta
“Dopamine D1 receptor partial agonist; Dopamine D5 receptor partial agonist”ChEMBL 37, by rule
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06895356Healthy Volunteer · United States | 1 | Completed | AbbVie | Jun 16, 2025 | 83 |
| NCT05610189Parkinson Disease · United States | 1 | Completed | AbbVie | Dec 12, 2023 | 25 |
| NCT05581823Parkinson Disease · United States | 1 | Completed | AbbVie | Jan 27, 2023 | 16 |
| NCT05404542Renal Insufficiency · United States | 1 | Completed | AbbVie | Aug 14, 2023 | 14 |
| NCT05404529Hepatic Impairment · United States | 1 | Completed | AbbVie | Jan 24, 2023 | 32 |
| NCT04760769Parkinson Disease · United States, Australia, Bulgaria and more | 3 | Completed | AbbVie | Dec 1, 2025 | 992 |
| NCT04542499Parkinson Disease · United States, Australia, Bulgaria and more | 3 | Completed | AbbVie | Jan 29, 2024 | 507 |
| NCT04295642Parkinson Disease · United States | 1 | Completed | AbbVie | Jul 23, 2021 | 24 |
| NCT04241393Healthy Subjects · United States | 1 | Completed | AbbVie | Nov 8, 2020 | 12 |
| NCT04223193Parkinson Disease · United States, Australia, France and more | 3 | Completed | AbbVie | Oct 1, 2024 | 304 |
| NCT04201093Parkinson Disease · United States, Australia, Bulgaria and more | 3 | Completed | AbbVie | Jun 28, 2024 | 529 |
| NCT03185481Parkinson Disease · United States | 2 | Terminated | Pfizer | Oct 24, 2017 | 5 |
| NCT03121664Healthy · Belgium | 1 | Completed | Pfizer | Sep 14, 2017 | 11 |
| NCT02847650Parkinson Disease · United States, France, Germany and more | 2 | Terminated | Pfizer | Jan 29, 2018 | 57 |
| NCT02687542Parkinson Disease · United States, Canada, France and more | 2 | Terminated | Pfizer | Nov 10, 2017 | 108 |
| NCT02373072Parkinson Disease · United States, Belgium | 1 | Completed | Pfizer | Feb 2016 | 18 |
| NCT02262767Healthy · Belgium | 1 | Completed | Pfizer | Dec 2014 | 9 |
| NCT02224664Parkinson Disease · United States, Belgium | 1 | Completed | Pfizer | Mar 2016 | 50 |
| NCT02066909Healthy · United States | 1 | Completed | Pfizer | Apr 2015 | 77 |
| NCT01981694Healthy · United States | 1 | Completed | Pfizer | Feb 2014 | 18 |
How it is read
Names in the registry
- “Tavapadon”, 10 entries
- “PF-06649751”, 9 entries
- “0.5 mg PF-06649751”, 2 entries
- “CVL-751”, 1 entry
- “PF-06649751 low dose (1 mg QD)”, 1 entry
Codes read as this program: PF06649751.
Conditions, from the studies’ own filings
- Parkinson Disease, 12 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.